CD160 Expression in Corneal Vessels

Status Recruiting

Clinical Trial Summary

Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis

Clinical Trial Description

After informed consent, patients enrolled for corneal graft surgery at the Robert Debré University Hospital, Reims, France, will be included. Routine general and eye examination including cornea photographs will be performed. During surgery, a quarter of patients' cornea and of donors' corneoscleral rim will be spared for immunohistochemistry analyzes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05009407
Study type	Observational
Source	CHU de Reims
Contact	Alexandre DENOYER
Phone	03 26 78 78 88
Email	adenoyer@chu-reims.fr
Status	Recruiting
Phase
Start date	April 21, 2021
Completion date	July 21, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06106932` - GnRH-a on Angiogenesis of Endometriosis	N/A
Completed	`NCT04974983` - Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma
Recruiting	`NCT04566952` - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer	Phase 2
Recruiting	`NCT04145505` - Micrometastases and Angiogenesis in Colon Cancer. Prognostic Value of VEGF.
Active, not recruiting	`NCT02396888` - Effects of Local Insulin on Wound Angiogenesis	Phase 3
Completed	`NCT03705247` - The Role of Bleeding at Implant Placement
Recruiting	`NCT04556071` - Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	Phase 2
Completed	`NCT04609332` - Endothelial Damage and Angiogenesis Biomarkers During COVID-19
Completed	`NCT03162588` - Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya	Phase 1/Phase 2
Recruiting	`NCT04772001` - Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer	N/A
Not yet recruiting	`NCT04807166` - Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer	Phase 2
Completed	`NCT04310280` - Effects of Local Insulin on Varicose Ulcers for Wound Healing	Phase 3
Completed	`NCT04670107` - The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy	Phase 1/Phase 2
Completed	`NCT00727948` - The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy	Early Phase 1
Completed	`NCT02603406` - Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits	Phase 2
Recruiting	`NCT03991871` - HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study	N/A
Completed	`NCT00744536` - Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS	Phase 2
Completed	`NCT00728598` - Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis	N/A
Active, not recruiting	`NCT04851054` - Postoperative VEGF and Recurrence After Colon Cancer Surgery
Not yet recruiting	`NCT02865304` - The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients	Phase 3